The product "oral recombinant Helicobacter pylori vaccine" independently developed by the company took the lead in completing phase III clinical trials at home and abroad and obtained the national first-class new drug certificate. With completely independent intellectual property rights, it has been included in the national key scientific research and industrialization projects, the ninth five-year plan national key scientific and technological projects, the first batch of key national 863 biotechnology projects in the tenth five-year plan, the ninth five-year plan military medical and health research fund projects, Chongqing key scientific and technological projects and high-tech industrialization projects. On April 23, 2009, the Ministry of Science and Technology held a press conference in Beijing, especially for the company's independent product "oral recombinant Helicobacter pylori vaccine", announcing the successful development of the world's first gastropathy vaccine.